Dyne Therapeutics (DYN) Competitors $9.05 +0.11 (+1.23%) Closing price 03:57 PM EasternExtended Trading$8.99 -0.06 (-0.62%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN vs. AKRO, PCVX, RYTM, KRYS, CYTK, ZLAB, PTCT, MRUS, ACLX, and ACADShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Akero Therapeutics (AKRO), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS), Cytokinetics (CYTK), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Merus (MRUS), Arcellx (ACLX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. Its Competitors Akero Therapeutics Vaxcyte Rhythm Pharmaceuticals Krystal Biotech Cytokinetics Zai Lab PTC Therapeutics Merus Arcellx ACADIA Pharmaceuticals Akero Therapeutics (NASDAQ:AKRO) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings. Do insiders & institutionals hold more shares of AKRO or DYN? 96.7% of Dyne Therapeutics shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by insiders. Comparatively, 14.1% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger valuation and earnings, AKRO or DYN? Akero Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$252.06M-$1.95-26.67Dyne TherapeuticsN/AN/A-$317.42M-$3.59-2.52 Do analysts prefer AKRO or DYN? Akero Therapeutics currently has a consensus target price of $82.50, suggesting a potential upside of 58.61%. Dyne Therapeutics has a consensus target price of $41.13, suggesting a potential upside of 354.42%. Given Dyne Therapeutics' higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is AKRO or DYN more profitable? Akero Therapeutics' return on equity of -15.19% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -15.19% -13.97% Dyne Therapeutics N/A -52.83%-48.84% Which has more risk & volatility, AKRO or DYN? Akero Therapeutics has a beta of -0.15, indicating that its stock price is 115% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Does the media favor AKRO or DYN? In the previous week, Dyne Therapeutics had 10 more articles in the media than Akero Therapeutics. MarketBeat recorded 15 mentions for Dyne Therapeutics and 5 mentions for Akero Therapeutics. Akero Therapeutics' average media sentiment score of 0.90 beat Dyne Therapeutics' score of 0.32 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDyne Therapeutics beats Akero Therapeutics on 8 of the 13 factors compared between the two stocks. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$2.44B$5.54B$8.95BDividend YieldN/A1.77%5.38%4.08%P/E Ratio-2.528.8627.3820.03Price / SalesN/A680.42419.46118.60Price / CashN/A157.0736.6357.47Price / Book1.464.638.085.67Net Income-$317.42M$31.34M$3.16B$248.47M7 Day Performance-9.95%0.84%2.12%2.90%1 Month Performance-31.80%7.92%4.43%5.75%1 Year Performance-73.45%1.87%35.62%21.36% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics3.4979 of 5 stars$9.05+1.2%$41.13+354.4%-74.2%$1.02BN/A-2.52100AKROAkero Therapeutics3.7421 of 5 stars$53.36-5.0%$82.50+54.6%+131.8%$4.25BN/A-27.3630Insider TradePCVXVaxcyte1.7733 of 5 stars$32.51-0.2%$136.50+319.9%-56.3%$4.19BN/A-8.15160News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.8053 of 5 stars$63.19+0.7%$77.31+22.3%+58.1%$4.02B$136.86M-22.49140KRYSKrystal Biotech4.5247 of 5 stars$137.46-1.0%$211.13+53.6%-20.4%$3.97B$333.45M33.04210Trending NewsAnalyst RevisionCYTKCytokinetics4.3223 of 5 stars$33.04-0.4%$70.92+114.7%-37.3%$3.95B$18.47M-6.25250Positive NewsZLABZai Lab3.4124 of 5 stars$34.97+0.7%$54.28+55.2%+104.3%$3.88B$398.99M-14.041,869Analyst ForecastInsider TradeAnalyst RevisionGap UpPTCTPTC Therapeutics4.3213 of 5 stars$48.84-2.0%$65.00+33.1%+61.7%$3.87B$1.77B7.501,410Analyst RevisionMRUSMerus1.4798 of 5 stars$52.60-0.7%$84.64+60.9%+0.5%$3.64B$54.73M-12.8937ACLXArcellx2.8098 of 5 stars$65.85+0.8%$111.23+68.9%+24.6%$3.63B$107.94M-22.0280Positive NewsACADACADIA Pharmaceuticals4.6934 of 5 stars$21.57-2.5%$27.88+29.2%+34.1%$3.61B$996.28M15.74510 Related Companies and Tools Related Companies Akero Therapeutics Competitors Vaxcyte Competitors Rhythm Pharmaceuticals Competitors Krystal Biotech Competitors Cytokinetics Competitors Zai Lab Competitors PTC Therapeutics Competitors Merus Competitors Arcellx Competitors ACADIA Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYN) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DYN Stock Alerts